Ovarian reserve function decline
Conditions
Interventions
Experimental Group 1 (Probiotics + Electroacoustic Ultrasound Combined Treatment Group):During the intermenstrual period, the patient received treatment using an electro-ultrasound therapy device (pro
Experimental Group 2 (Placebo + Electroacoustic Group):During the intermenstrual period, the patient received treatment using an electro-ultrasound therapy device (produced by Nanjing Malingde Medical
Experimental Group 3 (Probiotics + Mock Treatment Device Group):During the intermenstrual period, the pseudo-treatment device (produced by Nanjing Malingde Medical Technology Co., Ltd.) was used for t
Sponsors
Rugao People's Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1.Female patients of Rugao People's Hospital (aged 18-45); 2. Clinical diagnosis: Meet the DOR criteria (at least meet the following 2 items): (1). At least 4 weeks interval, at least 2 AMH 10 IU/L (on the 2-3 days of menstruation); 3. Other requirements: In the past 3 months, no use of antibacterial drugs, probiotics or hormone drugs, no physical or traditional Chinese medicine treatment; 4. BMI: 18 < BMI < 30.
Exclusion criteria
Exclusion criteria: 1. Pregnant or postpartum women; smokers, heavy drinkers; 2. Reproductive system diseases: Polycystic Ovary Syndrome (PCOS), endometriosis (not treated by surgery), history of bilateral oophorectomy; patients with pelvic malignant tumors; patients with high-grade squamous intraepithelial lesion of the cervix; patients with atypical endometrial hyperplasia and uterine fibroids; uterine fibroids (types 0, 1, 2) or a single fibroid larger than 6cm, multiple uterine fibroids larger than 2 months of pregnancy; active bleeding in the reproductive tract or other organs; surgical incisions on the pelvic and abdominal wall or vagina within the last 3 months; 3. Systemic diseases: Acute stage of urinary reproductive system or other parts of the body infection; hyperthyroidism; acute stage of fever or infectious diseases; accompanied by dementia, unstable epilepsy, neurological diseases, unable to actively cooperate with treatment; history of thrombotic diseases, abnormal heart, lung and liver-kidney functions; uncontrolled hypertension or diabetes; history of cerebrovascular accident; smokers; 4. Drug interference: Long-term use of immunosuppressants or intestinal microecological regulators; 5. Poor compliance: Unable to complete follow-up or refused to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anti-Müllerian hormone(AMH);Number of antral follicle development; | — |
Countries
China
Contacts
Public ContactZongli Ma
Rugao People's Hospital
Outcome results
None listed